NASDAQ
RLAY

Relay Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Relay Therapeutics Inc Stock Price

Vitals

Today's Low:
$9.67
Today's High:
$10.33
Open Price:
$9.74
52W Low:
$9.28
52W High:
$25.89
Prev. Close:
$9.8
Volume:
751625

Company Statistics

Market Cap.:
$1.35 billion
Book Value:
6.643
Revenue TTM:
$942000
Operating Margin TTM:
-39958.28%
Gross Profit TTM:
$1.38 million
Profit Margin:
0%
Return on Assets TTM:
-25.41%
Return on Equity TTM:
-43.33%

Company Profile

Relay Therapeutics Inc had its IPO on 2020-07-16 under the ticker symbol RLAY.

The company operates in the Healthcare sector and Biotechnology industry. Relay Therapeutics Inc has a staff strength of 345 employees.

Stock update

Shares of Relay Therapeutics Inc opened at $9.74 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.67 - $10.33, and closed at $9.86.

This is a +0.61% increase from the previous day's closing price.

A total volume of 751,625 shares were traded at the close of the day’s session.

In the last one week, shares of Relay Therapeutics Inc have slipped by -10.61%.

Relay Therapeutics Inc's Key Ratios

Relay Therapeutics Inc has a market cap of $1.35 billion, indicating a price to book ratio of 2.1162 and a price to sales ratio of 1224.6414.

In the last 12-months Relay Therapeutics Inc’s revenue was $942000 with a gross profit of $1.38 million and an EBITDA of $-371676992. The EBITDA ratio measures Relay Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Relay Therapeutics Inc’s operating margin was -39958.28% while its return on assets stood at -25.41% with a return of equity of -43.33%.

In Q2, Relay Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 67.4%.

Relay Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Relay Therapeutics Inc’s profitability.

Relay Therapeutics Inc stock is trading at a EV to sales ratio of 662.0353 and a EV to EBITDA ratio of -3.8635. Its price to sales ratio in the trailing 12-months stood at 1224.6414.

Relay Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$962.02 million
Total Liabilities
$71.58 million
Operating Cash Flow
$0
Capital Expenditure
$1.50 million
Dividend Payout Ratio
0%

Relay Therapeutics Inc ended 2024 with $962.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $962.02 million while shareholder equity stood at $810.12 million.

Relay Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $71.58 million in other current liabilities, 122000.00 in common stock, $-1251353000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $145.90 million and cash and short-term investments were $871.57 million. The company’s total short-term debt was $4,610,000 while long-term debt stood at $0.

Relay Therapeutics Inc’s total current assets stands at $884.35 million while long-term investments were $0 and short-term investments were $725.67 million. Its net receivables were $78000.00 compared to accounts payable of $14.78 million and inventory worth $9.31 million.

In 2024, Relay Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.50 million.

Comparatively, Relay Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$9.86
52-Week High
$25.89
52-Week Low
$9.28
Analyst Target Price
$26.04

Relay Therapeutics Inc stock is currently trading at $9.86 per share. It touched a 52-week high of $25.89 and a 52-week low of $25.89. Analysts tracking the stock have a 12-month average target price of $26.04.

Its 50-day moving average was $11.26 and 200-day moving average was $14.41 The short ratio stood at 23.18 indicating a short percent outstanding of 0%.

Around 241.6% of the company’s stock are held by insiders while 11076.2% are held by institutions.

Frequently Asked Questions About Relay Therapeutics Inc

The stock symbol (also called stock or share ticker) of Relay Therapeutics Inc is RLAY

The IPO of Relay Therapeutics Inc took place on 2020-07-16

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Nuvalent Inc (NUVL)
$46.98
-1.12
-2.33%
$12.95
-0.15
-1.11%
$0
0
+11.76%
$4.32
-0.44
-9.24%
$7.29
0.67
+10.12%
$6.3
-0.45
-6.67%
$62.38
-6.62
-9.59%
$2.57
0.02
+0.78%
STERIS plc (STE)
$226.86
-1.92
-0.84%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Address

399 Binney Street, Cambridge, MA, United States, 02139